BOP2-Comb: Bayesian Optimal Phase II Design for Optimizing Doses and Assessing Contribution of Components in Drug Combinations is a research paper published in Therapeutic Innovation & Regulatory Science (2025). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: P50CA281701, P50CA127001, P50CA221707, U24CA274212
National Institutes of Health
Grant: R01CA261978, R21LM014699
NCI NIH HHS
Grant: P50 CA127001
NLM NIH HHS
Grant: R21 LM014699
NCI NIH HHS
Grant: P50 CA221707
NCI NIH HHS
Grant: P50 CA281701
NCI NIH HHS
Grant: R01 CA261978
NCI NIH HHS
Grant: U24 CA274212
National Institutes of Health
Grant: 1R21LM014699-01
Novel designs for multi-arm multi-dose multi-stage platform trials
National Institutes of Health
Grant: 1R01CA261978-01
Bayesian Methods for Complex Precision Biotherapy Trials in Oncology
National Institutes of Health
Grant: 3P50CA127001-10S1
SPORE in Brain Cancer
National Institutes of Health
Grant: 1U24CA274212-01
Coordinating and Data Management Center for Translational and Basic Science Research in Early Lesions
National Institutes of Health
Grant: 5P50CA221707-03
MD Anderson Cancer Center SPORE in Gastrointestinal Cancer
FWCI
0.00
Citation Percentile
0.2%
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals